Axon DX LLC develops imaging technologies and products for the identification and research of rare cancer cells such as circulating tumor cells and circulating endothelial cells. The firm's primary platform, nCyte, is a research tool that allows for morphological and targets molecular characterization of Circulating Rare Cells. The platform offers enhanced scanning optical systems powered by AI and utilizes biomarkers for enhanced insight.
